OBJECTIVE: To evaluate the effect of first and second-trimester integrated screening so as to provide an efficient screening protocol for @entity1467 . METHODS: Using the dissociation-enhanced @entity17361 fluorescent immunoassay (DELFIA), the freebhCG (beta @entity1 chorionic gonadotropin), @entity15714 ( @entity15714 ) and NT (nuchal translucency) value of type B ultrasound were assayed in the pregnancy serum during the first trimester (11-13W(+6) d) and free @entity160 ( @entity160 ) during the second trimester(15-20W(+6) d). By the risk calculation software, the risks during both trimesters and their integrated risk were calculated for each @entity1 respectively. Amniocentesis and venepuncture were employed for diagnosing the high-risk @entity1 (> 1/270). Electronic network follow-up was carried out after delivery. RESULTS: In a total of 4237 pregnant @entity1 , 98 were found to carry a high risk during the first trimester, 241 during the second trimester and 101 during the integrated screening respectively. And 2, 3 and 4 cases were diagnosed with Down's symptom at a detection rate of 50%, 75% and 100% and a detection efficiency of 1:50, 1:80 and 1:25 respectively. CONCLUSION: Integrated screening is superior to either the first or second-trimester screening. With a lower false positive rate and a higher detection rate, it reduces the chance of invasive puncture. Advanced type B ultrasonic technology is needed to improve the first-trimester diagnostic efficiency and to develop a better integrated screening protocol.

[First trimester and second-trimester integrated screening for XXXX ].

@entity1 :: ('9606', 'Species') :: ['women', 'human', 'patients', 'patient'] @entity160 :: ('174', 'Gene') :: ['alpha fetoprotein', 'bhCG and AFP'] @entity1467 :: ('MESH:D004314', 'Disease') :: ["Down's syndrome"] @entity17361 :: ('CHEBI:33319', 'Chemical') :: ['lanthanide'] @entity15714 :: ('5069', 'Gene') :: ['pregnancy associated plasma protein-A', 'PAPP-A']
@entity1467 :: (MESH:D004314,Disease) :: ['Down's syndrome']
